| 70.16 0.05 (0.07%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 84.51 | 1-year : | 98.71 |
| Resists | First : | 72.36 | Second : | 84.51 |
| Pivot price | 68.01  |
|||
| Supports | First : | 50.54 | Second : | 37.06 |
| MAs | MA(5) : | 69.45 |
MA(20) : | 65.84 |
| MA(100) : | 39.19 |
MA(250) : | 0 | |
| MACD | MACD : | 5.7 |
Signal : | 6.2 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 81.2 |
| RSI | RSI(14): 69.9 |
|||
| 52-week | High : | 72.36 | Low : | 9.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARWR ] has closed below upper band by 28.7%. Bollinger Bands are 11% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 70.6 - 70.81 | 70.81 - 71.05 |
| Low: | 68.36 - 68.62 | 68.62 - 68.91 |
| Close: | 69.71 - 70.09 | 70.09 - 70.53 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Fri, 26 Dec 2025
Voya Investment Management LLC Has $4.74 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Wed, 24 Dec 2025
76,408 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by HBK Sorce Advisory LLC - MarketBeat
Tue, 23 Dec 2025
Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells $909,688.70 in Stock - MarketBeat
Tue, 23 Dec 2025
First Week of February 2026 Options Trading For Arrowhead Pharmaceuticals (ARWR) - Nasdaq
Tue, 23 Dec 2025
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - Business Wire
Tue, 16 Dec 2025
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching - ts2.tech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 136 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 84.5 (%) |
| Shares Short | 11,840 (K) |
| Shares Short P.Month | 11,780 (K) |
| EPS | -0.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.43 |
| Profit Margin | -0.3 % |
| Operating Margin | 17.2 % |
| Return on Assets (ttm) | 4.8 % |
| Return on Equity (ttm) | 8.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 6.1 |
| Sales Per Share | 6.1 |
| EBITDA (p.s.) | 0.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 180 (M) |
| Levered Free Cash Flow | 106 (M) |
| PE Ratio | -7016.01 |
| PEG Ratio | 0 |
| Price to Book value | 20.45 |
| Price to Sales | 11.48 |
| Price to Cash Flow | 53.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|